MCID: HDR002
MIFTS: 54

Hidradenitis Suppurativa

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Hidradenitis Suppurativa

MalaCards integrated aliases for Hidradenitis Suppurativa:

Name: Hidradenitis Suppurativa 12 73 20 43 42 44 15 17 70 32
Acne Inversa 20 43 36 39
Hidradenitides, Suppurative 43
Suppurative Hidradenitides 43
Hidradenitis, Suppurative 43
Suppurative Hidradenitis 43
Acne Inversa, Familial 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2280
KEGG 36 H00681
MeSH 44 D017497
NCIt 50 C128429
SNOMED-CT 67 201204008
ICD10 32 L73.2
UMLS 70 C0162836

Summaries for Hidradenitis Suppurativa

MedlinePlus : 42 What is hidradenitis suppurativa (HS)? Hidradenitis suppurativa (HS) is a chronic skin disease. It causes painful, boil-like lumps that form under the skin. It often affects areas where the skin rubs together, such as your armpits and groin. The lumps become inflamed and painful. They often break open, causing abscesses that drain fluid and pus. As the abscesses heal, they can cause scarring of the skin. What causes hidradenitis suppurativa (HS)? The lumps in HS form because of blockages of the hair follicles. The blocked hair follicles trap bacteria, which leads to inflammation and rupture. In most cases, the cause of the blockages is unknown. Genetics, environment, and hormonal factors may play a role. Some cases of HS are caused by changes in certain genes. HS is not caused by bad hygiene, and it cannot be spread to others. Who is at risk for hidradenitis suppurativa (HS)? HS usually starts after puberty, usually in the teens or twenties. It is more common in Women People with a family history of HS People who are overweight or have obesity Smokers What are the symptoms of hidradenitis suppurativa (HS)? The symptoms of HS include Small pitted areas of skin containing blackheads Painful, red, lumps that get bigger and break open. This causes abscesses that drain fluid and pus. They may itch and have an unpleasant odor. The abscesses heal very slowly, recur over time, and can lead to scarring and tunnels under the skin HS can be mild, moderate, or severe: In mild HS, there are only one or a few lumps in one area of the skin. A mild case will often get worse, becoming a moderate disease. Moderate HS include recurrences of the lumps that get bigger and break open. The lumps form in more than one area of the body. With severe HS, there are widespread lumps, scarring, and chronic pain that may make it hard to move Because of the difficulty of dealing with the disease, people with HS are at risk for depression and anxiety. How is hidradenitis suppurativa (HS) diagnosed? There is no specific test for HS, and it is often misdiagnosed in the early stages. To make a diagnosis, your health care provider will ask about your medical history and your symptoms. He or she will look at the lumps on your skin and test a sample of the skin or pus (if there is any). What are the treatments for hidradenitis suppurativa? There is no cure for HS. Treatments focus on the symptoms, but they are not always effective for everyone. The treatments depend on how severe the disease is, and they include Medicines, including steroids, antibiotics, pain relievers, and medicines that flight inflammation. In mild cases, the medicines may be topical. This means that you apply them to your skin. Otherwise the medicines may be injected or taken orally (by mouth). Surgery for severe cases, to remove the lumps and scars It may also help if you can avoid things that can irritate your skin, by Wearing loose-fitting clothing Staying at a healthy weight Quitting smoking Avoiding heat and humidity Being careful not to injure your skin

MalaCards based summary : Hidradenitis Suppurativa, also known as acne inversa, is related to pyogenic sterile arthritis, pyoderma gangrenosum, and acne and acne, and has symptoms including painful nodules, pruritus and exanthema. An important gene associated with Hidradenitis Suppurativa is NCSTN (Nicastrin), and among its related pathways/superpathways are Wnt signaling pathway and Notch signaling pathway. The drugs Adalimumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A hidradenitis that is characterized by chronic inflammation of the apocrine sweat glands, has symptom painful nodules, abscesses, sinus tract formation, scarring, erythema, pruritis, and pain, and has material basis in chronic inflammation of the apocrine sweat glands leading to recurrent folliculitis and an accompanying immune response that worsens inflammation.

MedlinePlus Genetics : 43 Hidradenitis suppurativa, also known as acne inversa, is a chronic skin disease characterized by recurrent boil-like lumps (nodules) under the skin. The nodules become inflamed and painful. They tend to break open (rupture), causing abscesses that drain fluid and pus. As the abscesses heal, they produce significant scarring of the skin.The signs and symptoms of hidradenitis suppurativa appear after puberty, usually in a person's teens or twenties. Nodules are most likely to form in the armpits and groin. They may also develop around the anus, on the buttocks, or under the breasts. In some cases, nodules appear in other areas, such as the nape of the neck, waist, and inner thighs.The recurrent nodules and abscesses cause chronic pain and can lead to self-consciousness, social isolation, and depression. Rarely, nodules on the buttocks can develop into a type of skin cancer called squamous cell carcinoma.

GARD : 20 Hidradenitis suppurativa (HS) is a chronic skin disease which causes painful, boil-like lumps that form under the skin and often secrete pus and blood. HS occurs most often in areas where skin rubs together, such as the armpits, groin, and under the breasts. Symptoms usually begin after puberty. The first sign may be a single pocket of pus (abscess) or hard lumps associated with hair follicles. The abscesses or lumps often change to painful swollen clusters of skin sores that drain a bloody and often, bad smelling discharge. As the sores heal, they may leave hardened, rope-like scars or form tunnels under the skin (called sinus tracks) that can be disfiguring and make movement difficult. As time goes by, the skin lesions occur more often and get worse over time. In most cases, the cause of HS is unknown. Genetics, environment, and hormonal factors may play a role. Some cases of HS have been associated with specific genes, including NCSTN, PSEN1, and PSENEN. Diagnosis of HS is made based on the clinical symptoms. Treatment of HS is determined by the severity of the symptoms and can include topical or oral antibiotics, anti-inflammatories, other medications, and surgery. Losing weight and stopping smoking can also improve the symptoms. HS causes chronic pain, significant scarring, and can be socially isolating, but is not life-threatening. People with HS have an increased chance to feel depressed or anxious, which, along with chronic pain, may impact their quality of life.

KEGG : 36 Acne inversa (AI), also known as hidradenitis suppurativa, is a chronic inflammatory disorder of hair follicles involving the apocrine gland-bearing areas of the body. Its characteristic features include recurrent formation of painful skin abscesses, fistulating sinuses, and disfiguring scars.

Wikipedia : 73 Hidradenitis suppurativa (HS), sometimes known as acne inversa or Verneuil's disease, is a long-term... more...

Related Diseases for Hidradenitis Suppurativa

Diseases related to Hidradenitis Suppurativa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 609)
# Related Disease Score Top Affiliating Genes
1 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 32.2 NLRP3 MEFV IL1B
2 acne 31.8 TNF PSENEN PSEN1 NCSTN IL1B IL1A
3 pyoderma gangrenosum 31.4 TNF NOD2 NLRP3 MEFV
4 pyoderma 31.2 TNF NOD2 NLRP3 MEFV IL1B
5 crohn's colitis 31.2 TNF NOD2 IL1B IFNG
6 ulcerative colitis 30.9 TNF NOD2 IL1B IL17A IFNG
7 spondyloarthropathy 1 30.9 TNF NOD2 IL17A
8 amyloidosis 30.9 TNF PSEN1 NLRP3 MEFV IL1B
9 rosacea 30.8 TNF IL17A CAMP
10 brucellosis 30.8 TNF MEFV IL17A IFNG
11 neutrophilic dermatosis, acute febrile 30.6 TNF MEFV IL1B
12 dermatitis 30.6 TNF NOD2 IL1B IL1A IL17A IFNG
13 anal canal squamous cell carcinoma 30.6 PSENEN NCSTN
14 reactive arthritis 30.6 TNF IL1B IL17A IFNG
15 histiocytosis 30.6 TNF IL17A IFNG
16 alopecia areata 30.5 TNF IL1B IL1A IL17A IFNG
17 acute cystitis 30.5 TNF IL1B CAMP
18 colitis 30.5 TNF NOD2 IL1B IL17A IFNG
19 keratoconjunctivitis 30.4 TNF IL17A IFNG
20 skin disease 30.4 TNF KRT10 IL1B IL1A IL17D IL17A
21 keratitis, hereditary 30.4 TNF NLRP3 IL1B IL1A IL17A GJB2
22 iridocyclitis 30.4 TNF IL1B IL17A
23 pain agnosia 30.4 TNF PSENEN IL1B
24 bone inflammation disease 30.4 TNF NLRP3 IL1B IL1A IL17A IFNG
25 erysipelas 30.4 TNF MEFV IL1B
26 candidiasis 30.4 TNF IL1B IL17A IFNG
27 common cold 30.3 TNF IL1B IL17A
28 crohn's disease 30.3 TNF NOD2 NLRP3 MEFV IL26 IL1B
29 spondyloarthropathy 30.2 TNF LTA IL1B IL17A IFNG
30 familial mediterranean fever 30.2 TNF NOD2 NLRP3 MEFV IL1B IL1A
31 mumps 30.2 TNF IL1B IFNG
32 arthropathy 30.2 TNF NLRP3 LTA IL1B IFNG
33 conjunctivitis 30.2 TNF NLRP3 IFNG
34 gout 30.1 TNF NLRP3 MEFV IL1B
35 bacterial meningitis 30.1 TNF IL1B IL17A IFNG
36 severe acute respiratory syndrome 30.1 TNF IL1B IFNG
37 exanthem 30.1 TNF NLRP3 MEFV IL1B IFNG
38 thyroiditis 30.1 TNF IL1B IL17A IFNG
39 food allergy 30.1 TNF IL17A IFNG
40 eye disease 30.1 TNF IL1B IL1A IL17A IFNG
41 bacterial infectious disease 30.1 TNF NOD2 IL1B IL1A IL17A IFNG
42 necrotizing fasciitis 30.1 LTA IL1B CAMP
43 pulmonary sarcoidosis 30.0 TNF IL12RB1 IFNG
44 fasciitis 30.0 TNF LTA IFNG
45 spondylitis 30.0 TNF NOD2 LTA IL1B IL17A IFNG
46 chorioretinitis 30.0 TNF NOD2 IL1B IL17A IFNG
47 osteomyelitis 30.0 TNF NOD2 NLRP3 MEFV IL1B IL1A
48 diarrhea 30.0 TNF NOD2 IL1B IFNG
49 periodontitis 30.0 TNF IL1B IL1A IL17A IFNG
50 chlamydia 30.0 TNF IL1B IL1A IL17A IFNG

Graphical network of the top 20 diseases related to Hidradenitis Suppurativa:



Diseases related to Hidradenitis Suppurativa

Symptoms & Phenotypes for Hidradenitis Suppurativa

Symptoms:

12
  • painful nodules

UMLS symptoms related to Hidradenitis Suppurativa:


pruritus; exanthema

GenomeRNAi Phenotypes related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 IL17A IL1A IL1B LTA NLRP3 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 IL17A IL1B LTA NLRP3 NOD2 PSEN1

MGI Mouse Phenotypes related to Hidradenitis Suppurativa:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CAMP IFNG IL12RB1 IL17A IL1A IL1B
2 immune system MP:0005387 10 CAMP GJB2 IFNG IL12RB1 IL17A IL1A
3 integument MP:0010771 9.7 GJB2 IFNG IL12RB1 IL17A IL1A IL1B
4 skeleton MP:0005390 9.36 GJB2 IFNG IL12RB1 IL17A IL1B LTA

Drugs & Therapeutics for Hidradenitis Suppurativa

Drugs for Hidradenitis Suppurativa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3 Anesthetics Phase 4
4 Antirheumatic Agents Phase 4
5 Anti-Inflammatory Agents Phase 4
6 Triamcinolone hexacetonide Phase 4
7 Triamcinolone diacetate Phase 4
8 Immunosuppressive Agents Phase 4
9 Immunologic Factors Phase 4
10 triamcinolone acetonide Phase 4
11 glucocorticoids Phase 4
12
Metformin Approved Phase 3 657-24-9 14219 4091
13
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
14 Hypoglycemic Agents Phase 3
15 Anti-Bacterial Agents Phase 3
16 Antibiotics, Antitubercular Phase 3
17
Brodalumab Approved, Investigational Phase 2 1174395-19-7
18
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
19
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
20
Infliximab Approved Phase 2 170277-31-3
21
Ustekinumab Approved, Investigational Phase 2 815610-63-0
22
Etanercept Approved, Investigational Phase 2 185243-69-0
23
Tofacitinib Approved, Investigational Phase 2 477600-75-2
24
Upadacitinib Approved, Investigational Phase 2 1310726-60-3 58557659
25
Methylene blue Approved, Investigational Phase 2 61-73-4
26
Polyestradiol phosphate Approved Phase 2 28014-46-2
27
Ethinyl Estradiol Approved Phase 2 57-63-6 5991
28
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
29
Drospirenone Approved Phase 2 67392-87-4 68873
30
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
31
Lysine Approved, Nutraceutical Phase 2 56-87-1 5962
32 Dermatologic Agents Phase 2
33 Epidiolex Phase 2
34 Olive Phase 2
35 chlorophyllin Phase 2
36 Analgesics Phase 2
37 Anti-Inflammatory Agents, Non-Steroidal Phase 2
38 Analgesics, Non-Narcotic Phase 2
39 Interleukin 1 Receptor Antagonist Protein Phase 2
40 Complement System Proteins Phase 2
41 Antiparasitic Agents Phase 1, Phase 2
42 Antimalarials Phase 1, Phase 2
43 Antiprotozoal Agents Phase 1, Phase 2
44 Gastrointestinal Agents Phase 2
45 interferons Phase 2
46 Janus Kinase Inhibitors Phase 2
47 Protein Kinase Inhibitors Phase 2
48 Anti-Infective Agents Phase 2
49 Anti-Infective Agents, Local Phase 2
50 Gentian Phase 2

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02808975 Phase 4 Placebo;Adalimumab
2 Cost-effectiveness of Adalimumab With Adjuvant Surgery Versus Adalimumab Monotherapy in the Treatment of Hidradenitis Suppurativa' Recruiting NCT03221621 Phase 4 Adalimumab Injection
3 Hidradenitis Suppurativa Patients' Experience of Treatment With Adalimumab Not yet recruiting NCT04132388 Phase 4 Adalimumab
4 Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa Not yet recruiting NCT04582669 Phase 4 Intralesional Triamcinolone 10 mg/mL;Intralesional Triamcinolone 20 mg/mL;Intralesional Triamcinolone 40 mg/mL;Placebo
5 Spironolactone in the Treatment of Hidradenitis Suppurativa: A Prospective, Open-Label Proof-of-Concept and Dose-Ranging Study Withdrawn NCT04100083 Phase 4 Spironolactone 50 MG;Spironolactone 100mg;Spironolactone 200 mg
6 A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension) Completed NCT01635764 Phase 3
7 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II Completed NCT01468233 Phase 3
8 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I Completed NCT01468207 Phase 3
9 A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02904902 Phase 3 adalimumab
10 A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE). Recruiting NCT03713619 Phase 3 secukinumab;Placebo
11 A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE) Recruiting NCT03713632 Phase 3 Secukinumab;Placebo
12 A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT04179175 Phase 3 secukinumab
13 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT04242498 Phase 3 Bimekizumab
14 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT04242446 Phase 3 Bimekizumab
15 A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
16 Rediscovery of Metformin for the Chronic Disabling Auto-inflammatory Disease Hidradenitis Suppurativa Not yet recruiting NCT04649502 Phase 3
17 To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
18 A Phase Ⅱ, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Unknown status NCT03929835 Phase 2 Cannabis oil;Placebo
19 An Open-label Single Center Study to Evaluate the Efficacy of SILIQ™ (Brodalumab) for the Treatment of Moderate Hidradenitis Suppurativa Unknown status NCT03910803 Phase 2 Brodalumab
20 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
21 An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
22 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03487276 Phase 2 IFX-1;Placebo
23 A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2 Placebo
24 Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Completed NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
25 A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
26 Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
27 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
28 A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
29 Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
30 A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica) Completed NCT01704534 Phase 2 Ustekinumab
31 A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
32 A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
33 A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy Completed NCT02643654 Phase 2 MABp1;Placebo
34 A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03607487 Phase 2 INCB054707;Placebo
35 A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03569371 Phase 2 INCB054707
36 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT04019041 Phase 2 bermekimab;placebo
37 A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa Completed NCT00107991 Phase 2 etanercept
38 An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
39 A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03248531 Phase 2 Bimekizumab;Adalimumab
40 A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
41 A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA Recruiting NCT04092452 Phase 2 PF-06650833;PF-06700841;PF-06826647;Placebo
42 A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03827798 Phase 2 CFZ533;Placebo to CFZ533;LYS006;Placebo to LYS006
43 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa Recruiting NCT04493502 Phase 2 Placebo;LY3041658
44 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa Recruiting NCT04476043 Phase 2 INCB054707;Placebo
45 Proof of Concept Study on LTX-109 as Treatment for Hidradenitis Suppurativa Recruiting NCT04756336 Phase 1, Phase 2 LTX-109 gel, 3% w/w
46 Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down Syndrome Recruiting NCT04246372 Phase 2 Tofacitinib
47 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT04430855 Phase 2 Upadacitinib;Placebo Upadacitinib
48 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT03852472 Phase 2 Avacopan
49 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT03926169 Phase 2 Risankizumab;Placebo for risankizumab
50 Exploratory Trial of Ruxolitinib 1.5% Cream for the Treatment of Early Stage Hidradenitis Suppurativa Not yet recruiting NCT04414514 Phase 2 Ruxolitinib 1.5% Cream

Search NIH Clinical Center for Hidradenitis Suppurativa

Cochrane evidence based reviews: hidradenitis suppurativa

Genetic Tests for Hidradenitis Suppurativa

Anatomical Context for Hidradenitis Suppurativa

MalaCards organs/tissues related to Hidradenitis Suppurativa:

40
Skin, Heart, Liver, Eye, Ovary, Bone, Kidney

Publications for Hidradenitis Suppurativa

Articles related to Hidradenitis Suppurativa:

(show top 50) (show all 2985)
# Title Authors PMID Year
1
Self-Reported Pain Alleviating Methods in Patients with Hidradenitis Suppurativa. 42 61
33232705 2021
2
Sexuality in Patients with Hidradenitis Suppurativa: Beliefs, Behaviors and Needs. 42 61
33260862 2020
3
Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. 42 61
33147660 2020
4
Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. 20 61
29183082 2017
5
Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. 20 61
26831295 2016
6
Chronic Systemic Inflammatory Skin Disease as a Risk Factor for Cardiovascular Disease. 61
33607473 2021
7
Outcomes of Routine Diabetes Screening for Patients with Hidradenitis Suppurativa. 61
32910937 2021
8
Potential Predictive Biomarkers of Adalimumab Response in Patients with Hidradenitis Suppurativa. 61
33811319 2021
9
Recurrence Rates Following Reconstruction Strategies After Wide Excision of Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. 61
33795566 2021
10
Long-term antibiotic use for the treatment of hidradenitis suppurativa consistent with guideline recommendations. 61
33202036 2021
11
Superficial fungal infections and patients with hidradenitis suppurativa: a study under the Danish Blood Donor Study. 61
33006774 2021
12
Impact of 970 nm photobiomodulation therapy on wound healing in cellular models of hidradenitis suppurativa. 61
32647934 2021
13
Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. 61
33247833 2021
14
Authors' reply to the comment "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa". 61
33253838 2021
15
Comment on "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa". 61
33253840 2021
16
Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity. 61
33030217 2021
17
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 61
33608949 2021
18
Hidradenitis suppurativa - The role of interleukin-17, the aryl hydrocarbon receptor and the link to a possible fungal aetiology. 61
33607406 2021
19
Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa. 61
33502014 2021
20
Vulvar hidradenitis suppurativa: Clinical cross-sectional study of 25 patients. 61
33547675 2021
21
Clinical Epidemiology and Management of Hidradenitis Suppurativa. 61
33706337 2021
22
Drug repurposing through drug-gene interaction profiles for hidradenitis suppurativa/acne inversa treatment. 61
33007126 2021
23
European registry for hidradenitis suppurativa: state of play. 61
33135255 2021
24
Metascoring Hidradenitis suppurativa. 61
33131129 2021
25
Preparing the hair follicle canal for hair shaft emergence. 61
33025661 2021
26
Synergistic multiple early therapy (SMET) for inflammatory diseases with pathogenic autoinflammatory feedback circuits. 61
33797104 2021
27
Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? 61
33665949 2021
28
Hidradenitis suppurativa and perceived stigmatization in a diverse Canadian clinic population: a pilot study. 61
33095910 2021
29
Hidradenitis suppurativa: A review of post-operative outcomes. 61
32868233 2021
30
Plastic Surgical Management of Hidradenitis Suppurativa. 61
33620946 2021
31
Hidradenitis suppurativa lesions are associated with decreased collagen, decreased elastin, and increased neovascularization. 61
33757414 2021
32
Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series. 61
33242185 2021
33
Implementing Medical Chatbots: An Application on Hidradenitis Suppurativa. 61
33744903 2021
34
Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series. 61
31389375 2021
35
Evaluation of the laboratory parameters in hidradenitis suppurativa: Can we use new inflammatory biomarkers? 61
33527638 2021
36
Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study. 61
33760224 2021
37
In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes. 61
33766512 2021
38
Crystallized phenol for sacral hidradenitis suppurativa. 61
31259621 2021
39
Clinical and Power-Doppler ultrasound features related with persistence of fistulous tracts under treatment with adalimumab in hidradenitis suppurativa: 4 years of follow-up. 61
33486868 2021
40
Importance of Standardized Nomenclature to Advance Hidradenitis Suppurativa Research and Clinical Care. 61
33688911 2021
41
Reproductive Potential and Outcomes in Patients with Hidradenitis Suppurativa: Clinical Profile and Therapeutic Implications. 61
33810294 2021
42
Tildrakizumab as a potential long-term therapeutic agent for severe Hidradenitis Suppurativa: A 15 months experience of an Australian institution. 61
33729553 2021
43
Antidrug antibodies to tumour necrosis factor inhibitors in hidradenitis suppurativa: a systematic review. 61
33006769 2021
44
Cryptic deep dermatophytosis in a renal transplant recipient with hidradenitis suppurativa. 61
33665286 2021
45
Identifying Triggers for Hidradenitis Suppurativa Flare - A Patient Survey. 61
33665807 2021
46
Sonographic Evaluation of Hidradenitis Suppurativa with Smartphone-Linked Portable Ultrasound. 61
33684921 2021
47
Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study. 61
33660281 2021
48
Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary. 61
33688910 2021
49
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease. 61
31389737 2021
50
The link between hidradenitis suppurativa and phylloid hypomelanosis in partial trisomy-13 mosaicism: New evidences and further genetic/pathogenetic insights. 61
33715178 2021

Variations for Hidradenitis Suppurativa

Expression for Hidradenitis Suppurativa

Search GEO for disease gene expression data for Hidradenitis Suppurativa.

Pathways for Hidradenitis Suppurativa

Pathways related to Hidradenitis Suppurativa according to KEGG:

36
# Name Kegg Source Accession
1 Wnt signaling pathway hsa04310
2 Notch signaling pathway hsa04330
3 Neurotrophin signaling pathway hsa04722

Pathways related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 TNF PSEN1 NOD2 NLRP3 NCSTN MEFV
2
Show member pathways
13.81 TNF PSENEN PSEN1 NCSTN LTA IL26
3
Show member pathways
13.7 TNF LTA IL26 IL1B IL1A IL17D
4
Show member pathways
13.55 TNF LTA IL26 IL1B IL1A IL17A
5
Show member pathways
13.34 TNF NOD2 LTA IL1B IL1A IL17A
6
Show member pathways
13.32 TNF LTA IL26 IL1B IL1A IL17A
7
Show member pathways
12.84 TNF LTA IL1B IL1A IL17A IFNG
8
Show member pathways
12.82 TNF NLRP3 IL1B IL1A IFNG
9
Show member pathways
12.66 TNF LTA IL1B IL1A IFNG
10
Show member pathways
12.6 TNF IL1B IL1A IL17A IFNG
11
Show member pathways
12.59 TNF IL1B IL17A IL12RB1 IFNG
12
Show member pathways
12.42 TNF NOD2 NLRP3 IL1B
13
Show member pathways
12.32 TNF IL1B IL1A IFNG
14
Show member pathways
12.32 TNF IL1B IL17D IL17A IFNG
15
Show member pathways
12.3 TNF NOD2 IL1B IL1A IL17D IL17A
16
Show member pathways
12.28 TNF IL1B IL1A IFNG
17
Show member pathways
12.23 TNF NLRP3 IL1B IL17D
18
Show member pathways
12.22 PSENEN PSEN1 NCSTN IL1A
19
Show member pathways
12.22 TNF LTA IL1B IL1A IL17A IFNG
20
Show member pathways
12.18 TNF NLRP3 IL1B IL1A IFNG
21 12.1 TNF IL1B IL1A IFNG
22 12.09 TNF NLRP3 MEFV IL1B
23 12.08 TNF PSENEN PSEN1 NCSTN IL1B
24 12.06 TNF NOD2 NLRP3 MEFV IL1B CAMP
25 12 TNF IL1B IL1A IFNG
26 11.99 TNF NOD2 IL1B IL1A IFNG CAMP
27 11.97 TNF IL1B IL1A IL17A
28 11.96 TNF NOD2 LTA IL1B
29 11.8 TNF IL1B IL1A IL17A IFNG
30
Show member pathways
11.76 IL26 IL1B IL17A IL12RB1 IFNG
31 11.75 TNF IL1B IFNG
32 11.75 TNF NLRP3 IL1B IL1A
33
Show member pathways
11.7 PSENEN PSEN1 NCSTN
34
Show member pathways
11.62 TNF IL1B IL1A IFNG
35 11.6 TNF LTA IL1A
36
Show member pathways
11.57 TNF LTA IFNG
37 11.56 TNF IL1B IFNG
38 11.55 TNF IL1B IL1A
39 11.53 TNF IL1B IFNG
40 11.53 TNF IL1B IFNG
41 11.5 PSENEN PSEN1 NCSTN
42 11.45 TNF IL1B IL1A IFNG
43 11.39 TNF IL1B IFNG
44 11.39 NOD2 NLRP3 MEFV IL1B
45 11.35 TNF IL1B IL1A
46 11.34 TNF LTA IL1B IL17A IL12RB1 IFNG
47 11.26 TNF IL1B IL17A IFNG
48 11.17 NLRP3 IL1B IFNG
49 11.13 PSENEN PSEN1 NCSTN
50 11.13 TNF IL1B IL1A IFNG

GO Terms for Hidradenitis Suppurativa

Cellular components related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.85 TNF LTA KRT10 IL26 IL1B IL1A
2 extracellular region GO:0005576 9.73 TNF NLRP3 LTA KRT10 IL26 IL1B
3 gamma-secretase complex GO:0070765 8.8 PSENEN PSEN1 NCSTN

Biological processes related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.16 PSEN1 NLRP3 LTA IL1B IL1A IL17A
2 immune response GO:0006955 10.13 TNF LTA IL1B IL1A IL17A IFNG
3 positive regulation of gene expression GO:0010628 10.12 TNF PSEN1 IL1B IL1A IFNG
4 positive regulation of apoptotic process GO:0043065 10.09 TNF PSENEN PSEN1 NCSTN LTA
5 cell-cell signaling GO:0007267 10.04 LTA IL26 IL1B IL17A GJB2
6 positive regulation of protein phosphorylation GO:0001934 10.01 TNF PSEN1 IL1B IFNG CAMP
7 cytokine-mediated signaling pathway GO:0019221 10.01 TNF IL26 IL1B IL1A IL17A IL12RB1
8 response to lipopolysaccharide GO:0032496 10 NOD2 LTA IL1B GJB2
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNF NOD2 NLRP3 IL1B
10 defense response GO:0006952 9.99 TNF NOD2 NLRP3 CAMP
11 inflammatory response GO:0006954 9.95 TNF NLRP3 MEFV IL1B IL1A IL17D
12 ephrin receptor signaling pathway GO:0048013 9.9 PSENEN PSEN1 NCSTN
13 positive regulation of JNK cascade GO:0046330 9.9 TNF NOD2 IL1B
14 regulation of insulin secretion GO:0050796 9.89 TNF IL1B IFNG
15 protein processing GO:0016485 9.89 PSENEN PSEN1 NCSTN
16 cellular response to organic cyclic compound GO:0071407 9.89 TNF NOD2 IL1B
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF NOD2 IL1B
18 positive regulation of MAP kinase activity GO:0043406 9.88 TNF PSEN1 NOD2
19 humoral immune response GO:0006959 9.88 TNF LTA IFNG
20 positive regulation of interferon-gamma production GO:0032729 9.88 TNF LTA IL1B IL12RB1
21 positive regulation of interleukin-8 production GO:0032757 9.87 TNF NOD2 IL1B IL17D
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF IL1B IFNG
23 positive regulation of cytokine production GO:0001819 9.86 TNF IL26 IL1A IFNG
24 positive regulation of interleukin-12 production GO:0032735 9.85 NOD2 IL17A IFNG
25 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.85 TNF IL1B IL1A
26 defense response to Gram-positive bacterium GO:0050830 9.85 TNF NOD2 LTA IL17A CAMP
27 positive regulation of catalytic activity GO:0043085 9.83 PSENEN PSEN1 NCSTN
28 positive regulation of osteoclast differentiation GO:0045672 9.81 TNF IL17A IFNG
29 positive regulation of phagocytosis GO:0050766 9.81 TNF NOD2 IL1B IFNG
30 membrane protein ectodomain proteolysis GO:0006509 9.8 PSENEN PSEN1 NCSTN
31 membrane protein intracellular domain proteolysis GO:0031293 9.8 PSENEN PSEN1 NCSTN
32 positive regulation of glial cell proliferation GO:0060252 9.78 TNF LTA IL1B
33 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 TNF IL1B IFNG
34 astrocyte activation GO:0048143 9.77 TNF PSEN1 IFNG
35 positive regulation of tumor necrosis factor production GO:0032760 9.77 PSEN1 NOD2 IL1A IL17A IFNG
36 amyloid precursor protein catabolic process GO:0042987 9.75 PSENEN PSEN1 NCSTN
37 epithelial cell proliferation GO:0050673 9.73 PSEN1 NCSTN
38 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 IL1B IL17D
39 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL1B
40 cellular response to lipopolysaccharide GO:0071222 9.73 TNF NOD2 NLRP3 IL1B IL1A CAMP
41 negative regulation of amyloid-beta clearance GO:1900222 9.72 TNF IFNG
42 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
43 amyloid precursor protein metabolic process GO:0042982 9.72 PSENEN PSEN1 NCSTN
44 vascular endothelial growth factor production GO:0010573 9.71 TNF IL1B
45 cellular response to peptidoglycan GO:0071224 9.7 NOD2 CAMP
46 positive regulation of type 2 immune response GO:0002830 9.7 NOD2 NLRP3
47 amyloid-beta formation GO:0034205 9.7 PSENEN PSEN1 NCSTN
48 positive regulation of interleukin-23 production GO:0032747 9.69 IL17A IFNG
49 positive regulation of fever generation GO:0031622 9.69 TNF IL1B
50 positive regulation of immature T cell proliferation in thymus GO:0033092 9.68 IL1B IL1A

Molecular functions related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TNF LTA IL26 IL1B IL1A IL17D
2 growth factor receptor binding GO:0070851 8.96 PSEN1 NCSTN

Sources for Hidradenitis Suppurativa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....